OBJECTIVE： To evaluate efficacy， safety and econimics of etoposide/dacarbazine for pediatric Hodgkin lymphoma according to the requirements of WHO pediatric EMLc Expert Committee， and to provide the evidence whether etoposide and dacarbazine should be included in fifth edition of WHO EMLc. METHODS： Retrieved from the Cochrane Library， PubMed， Embase， WHO ICTRP， NGC database and Google scholar search systematically， clinical studies， guideline and systematic review about efficacy， safety and safety of etoposide/dacarbazine for pediatric Hodgkin lymphoma were collected from database establishment to Jan. 2015. The quality of systematic evaluation/Meta-analysis， RCT and observational research literature were evaluated by using AMSTAR， Cochrane handbook and ACROBAT-NRSI tool. The quality of evidence and recommended intensity were evaluated by using GRADE （2011）. RESULTS： Totally 8 literatures were included. For efficacy： one evidence-based guideline supported the use of etoposide for the treatment of pediatric Hodgkin lymphoma. Among 5 RCTs， progression-free survival （EFS） and overall survival （OS） of 2 schemes containing etoposide/dacarbazine were all higher than 75％， but there was no statistical significance in EFS and OS of 2 schemes containing dacarbazine， complete remission （CR） of 1 scheme containing etoposide， compared with other chemotherapy plan. For safety， adverse events of schemes containing etoposide/dacarbazine containing mainly included neutrophils， bone marrow suppression， lung toxicity， nausea and vomiting， and secondary malignant tumors， which were all tolerable. For economics， ABVD regimen was affordable for developed countries， but expensive for developing countries. GRADE results showed that evidence had moderate quality. CONCLUSIONS： It is recommended to include etoposide/dacarbazine for treatment of pediatric Hodgkin lymphoma into fifth edition of WHO pediatric EMLc.